Stifel analyst Eric Le Berrigaud upgraded Novartis to Buy from Hold with a price target of CHF 97, up from CHF 89. The analyst says his "icrementally positive stance" on Pluvicto for advanced prostate cancer and Kisqali for breast cancer more than offsets his more conservative view towards cholesterol drug Leqvio. Le Berrigaud expects a "reversal of investor sentiment towards Novartis."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS: